937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 937-P
Author(s):  
TSUNG-HUI WU ◽  
HARN-SHEN CHEN
Keyword(s):  
Glycemic Control ◽  
Cell Function ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Evaluating the Synergistic Activity of Metformin and Apple Cider Vinegar in Type 2 Diabetics

2020 ◽  
pp. 1-7
Author(s):  
Momina Abid ◽  
Farah Ahmed ◽  
Shehla Shaheen ◽  
Zahida Memon ◽  
M. Zaman Shaikh ◽  
...  
Keyword(s):  
Glycemic Control ◽  
The Body ◽  
Diabetic Patients ◽  
Synergistic Activity ◽  
Care Hospital ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Apple Cider ◽  
Type 2 Diabetic

Aims: The aim of this study was to observe the effect of Apple Cider Vinegar (ACV) in combination with Metformin on the Body Mass Index (BMI) and glycemic control of newly diagnosed type 2 diabetic patients. Study Design: Single arm pre post quasi experimental clinical trial. Place and Duration of Study: Department of Medicine of a tertiary care hospital and a Diabetes and Endocrinology clinic, based in Karachi, Pakistan from April to July 2019. Methodology: A total of 30 newly diagnosed type 2 diabetic patients were enrolled in the study (Males: 17; females: 13; age range: 27-55 years) after obtaining written informed consent. The parameters of Body weight, BMI, Fasting Blood Sugar (FBS) and Hemoglobin A1c (HbA1c) of each patient were assessed before and after 12 weeks of treatment with Metformin 750 mg plus 2 tablespoons of ACV per day. The baseline and post treatment values of the aforementioned were compared with each other. Results: In all the 30 patients assessed after 12 weeks of treatment, the weight was significantly reduced from 85.66±18.30 kg. to 82.96±18.43 kg with a consequently significant change in the BMI from 29.38±5.08 kg/m2 to 28.43±5.16 kg/m2. Moreover, the glycemic control, assessed as FBS and HbA1c also showed significant reduction in the FBS (127.76±9.17 to 121.23±9.54) and HbA1c (7.14±0.29 to 6.92±0.29) after 12 weeks of treatment in all 30 patients (p<0.01). Conclusion: Apple Cider Vinegar seems to be effective therapy in combination with metformin for newly diagnosed type 2 diabetic patients in improving glycemic control as well as augmenting weight reduction.

scholarly journals The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients

2021 ◽  
Vol 37 (7) ◽  
Author(s):  
Cengiz Karacaer ◽  
Taner Demirci ◽  
Hasret Cengiz ◽  
Ceyhun Varim ◽  
Ali Tamer
Keyword(s):  
Glycemic Control ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Objectives: We aimed to determine the effect of short-term intensive insulin therapy (SIIT) on long-term glycemic control in newly-diagnosed Type-2 diabetes mellitus (nT2DM) patients. Methods: In this retrospectively study conducted at Sakarya University Medical Faculty Training and Research Hospital Outpatient Clinic between 2016 and 2019, 65 nT2DM patients were enrolled soon after their SIIT was initiated and were followed for at least a year. Intensive insulin treatment was discontinued after three or 12 months in a total of 65 (23–73-year-old) patients who had been newly diagnosed with T2DM. Intensive insulin therapy was discontinued when glycemic control and the target Glycated Hemoglobin (HbA1c) level had been attained, after which oral anti-diabetic drug (OAD), long-term insulin, and diet therapies were pursued. Results: There was a significant decrease in mean HbA1c from 11.25±1.96% to 6.67±1.07%. Fasting plasma glucose (FPG) was found to be an independent predictor of whether intensive insulin therapy could be discontinued after three months in a model that included FPG, HbA1c, and body mass index measured at baseline. Patients with FPG >13.8 mmol/L were 7.6 times more likely to require intensive insulin therapy beyond three months. There were significant decreases in HbA1c and low-density lipoprotein-cholesterol concentration, but no change in C-peptide between baseline and 3 months of therapy. Conclusion: These results demonstrate that in nT2DM patients, intensive insulin therapy could be effective on long-term glycemic control and high FPG prior to three months of SIIT may predict poor long-term glycemic control. doi: https://doi.org/10.12669/pjms.37.7.4013 How to cite this:Karacaer C, Demirci T, Cengiz H, Varim C, Tamer A. The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4013 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients

2020 ◽  
Author(s):  
Yan Huang ◽  
Xia Han ◽  
Feng-fei Li ◽  
Yan-mei Liu ◽  
Zelong Liu ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Mean Amplitude ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Mean Glucose ◽  
The Relationship ◽  
Type 2 Diabetic ◽  
Glycemic Variations

Abstract Background Accumulated evidences indicate that elevated levels of circulating ErbB2 are closely associated with increased incidence of diabetes. However, the relationship between ErbB2 concentration and glycemic variations (GV) in type 2 diabetic (T2D) patients remains elucidated. The aim of this study was to assess whether there is an association between serum ErbB2 concentration and GV in newly diagnosed T2D patients. Methods This was a three-center, and observational study. Between April 2019 and July 2019, a total of 106 newly diagnosed T2D patients were recruited. All recruited subjects were admitted as inpatients and received anti-diabetes agents free during the study period. At baseline, fasting serum was collected for ErbB2 measurement and all recruited patients were subjected a prospective CGM for at least 3 days. The primary endpoint was the relationships between ErbB2 concentrations and GV in T2D patients. Results Data of a total of 95 subjects who met the inclusion criteria were analyzed at the endpoint. Subjects were divided into quartiles according to their serum ErbB2 concentrations. We observed that subjects with an elevated level of ErbB2 had a higher value of GV in terms of mean amplitude of glucose excursion (MAGE), standard deviation of mean glucose (SDMG), and the coefficient of variation (CV%) than those with lower levels (all P<0.05). Multiple linear regression analyzes after adjusting for confounder factors indicate that serum ErbB2 levels were significantly positively correlated with the MAGE (β=0.664, t=7.218, P<0.01), SD (β=0.469, t=5.125, P<0.01) and CV% (β=0.337, t=4.442, P<0.01), respectively. Conclusion Serum ErbB2 concentration was positively correlated to the glycemic variations in newly diagnosed T2D patients. Our data indicating that ErbB2 may be a potential treatment target for diabetic patients for improvement in glycemic control. Keywords Type 2 Diabetes, glycemic control, ErbB2

Sign in / Sign up

Export Citation Format

Share Document